β-Tryptase and quantitative mast-cell increase in a sudden infant death following hexavalent immunization

Forensic Science International

Volumn 179, Issue 2-3, 2008, Pages

  D'Errico, Stefano ^a   Neri, Margherita ^a   Riezzo, Irene ^a   Rossi, Giuseppina ^b   Pomara, Cristoforo ^a   Turillazzi, Emanuela ^a   Fineschi, Vittorio ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Hexavalent vaccine; Mast cell; Sudden infant death; Tryptase

Indexed keywords

BETA TRYPTASE; CORTICOSTEROID; TRYPTASE;

AEROSOL; APGAR SCORE; ARTICLE; CASE REPORT; DYSPNEA; FAMILY HISTORY; FEMALE; HUMAN; HYPERCAPNIA; HYPOTENSION; IMMUNIZATION; INFANT; LABORATORY TEST; LARYNGOSCOPY; MAST CELL; METABOLIC ACIDOSIS; PRIORITY JOURNAL; STRIDOR; SUDDEN INFANT DEATH SYNDROME;

EID: 47749113221     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2008.04.018     Document Type: Article

References (23)

1. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., De Stefano F., Black S.B., Mullooly J.P., and Thompson R.S. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112 (2003) 815-820
2. Brockow K., Vieluf D., Püschel K., Grosch J., and Ring J. Increased post-mortem serum mast-cell tryptase in a fatal anaphylactoid reaction to non-ionic radiocontrast medium. J. Allergy Clin. Immun. 104 (1999) 237-238
3. Buckley M.G., Variend S., and Walls A.F. Elevated serum concentrations of β-tryptase, but not α-tryptase, in Sudden Infant Death Syndrome (SIDS). An investigation of anaphylactic mechanisms. Clin. Exp. Allergy 31 (2001) 1696-1704
4. Chabot I., Goetghebeur M.M., and Grégoire J.P. The societal value of universal childhood vaccination. Vaccine 22 (2004) 1992-2005
5. Duclos P. A global perspective on vaccine safety. Vaccine 22 (2004) 2059-2063
6. Edston E., and van Hage-Hamsten M. β-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci. Int. 93 (1998) 135-142
7. Edston E., Eriksson O., and van Hage-Hamsten M. Mast cell tryptase in postmortem serum-reference values and confounders. Int. J. Leg. Med. 121 (2007) 275-280
8. Farrington C.P. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22 (2004) 2064-2070
9. Fineschi V., Cecchi R., Centini F., Paglicci Reattelli L., and Turillazzi E. Immunohistochemical quantification of pulmonary mast-cells and post-mortem blood dosage of tryptase and eosinophil cationic protein in 48 heroin-related deaths. Forensic Sci. Int. 120 (2001) 189-194
10. Immunization safety surveillance, Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization (WPRO/EPI/99.01.), World Health Organization, Regional Office for the Western Pacific, Manila, 1999.
11. Kwittken P.L., Rosen S., and Sweinberg S.K. MMR vaccine and neomycin allergy. Am. J. Dis. Child. 147 (1993) 128-129
12. Lleonart-Bellfill R., Cistero-Bahima A., Cerda-Trias M.T., and Olive-Perez A. Tetanus toxoid anaphylaxis. DICP 25 (1991) 870
13. Maurer W. Death following hexavalent vaccination. Vaccine 23 (2005) 5461-5453
14. Ottaviani G., Lavezzi A.M., and Matturri L. Sudden infant death syndrome (SIDS) shortly after hexavalent vaccination: another pathology in suspected SIDS?. Virchows Arch. 448 (2006) 100-104
15. Pool V., Braun M.M., Kelso J.M., Mootrey G., Chen R.T., Yunginger J.W., Jacobson R.M., Gargiullo P.M., and VAERS Team. US Vaccine Adverse Event Reporting System, Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 110 (2002) e71
16. Schmitt H.J., Siegrist C.A., Salmaso S., Law B., and Booy R. Reply to letter Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 24 (2006) 5781-5782
17. The European Agency for the Evaluation of Medicinal Products, EMEA reviews hexavalent vaccines: Hexavac and Infanrix Hexa, London, 28 April 2003.
18. The European Agency for the Evaluation of Medicinal Products, EMEA update on hexavalent vaccines: Hexavac and Infanrix Hexa, London, 1 Dicember 2003.
19. The Royal College of Pathologists and The Royal College of Paediatrics and Child Health, Sudden unexpected death in infancy, A multi-agency protocol for care and investigation, The report of a working group convened by The Royal College of Pathologists and The Royal College of Paediatrics and Child Health, From the Colleges' websites, www.rcpath.org and www.rcpch.ac.uk, 2004.
20. Vennemann M.M.T., Butterfaß-Bahloul T., Jorch G., Brinkmann B., Findeisen M., Sauerland C., Bajanowski T., Mitchell E.A., and The GeSID group. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 25 (2007) 336-340
21. von Kries R. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 24 (2006) 5783-5784
22. Zepp F., Knuf M., Heininger U., Jahn K., Collard A., Habermehl P., Schuerman L., and Sänger R. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22 (2004) 2226-2233
23. Zinka B., Rauch E., Buettner A., and Penning R. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 24 (2006) 5779-5780